他汀类药物与慢性乙型肝炎患者肝细胞癌风险
这项医院为基础的回顾性队列研究纳入7,713例慢性HBV感染者,分析他汀使用与肝细胞癌(HCC)发生风险的关系。中位随访7.2年,702例(9.1%)新发HCC;他汀使用与HCC风险降低相关(调整后HR=0.36,95%CI 0.19-0.68),且呈剂量依赖性。
要点
- 慢性HBV感染者中,他汀使用与HCC风险降低独立相关(调整后HR=0.36)。
- 他汀对HCC风险的降低呈剂量依赖性,累计defined daily doses越高风险越低。
- 该获益在所有预设亚组中均观察到,提示他汀可能具有化学预防作用。
核心结论
- 在慢性HBV感染者中,他汀使用与HCC发生风险降低相关,提示他汀可能具有化学预防作用,值得前瞻性研究验证。
研究设计与样本
- 医院为基础的回顾性队列研究,纳入2008年1月至2012年12月间7,713例慢性HBV感染者。
- 他汀使用者定义为随访期间累计使用至少28个defined daily doses(n=713)。
- 采用含时间依赖协变量的多因素Cox回归模型分析他汀使用与HCC发病的关系。
主要发现
- 中位随访7.2年(最短-最长:0.5-9.9年),702例(9.1%)新发HCC。
- 他汀使用与HCC风险降低相关(调整后HR=0.36,95%CI 0.19-0.68),校正年龄、性别、肝硬化、糖尿病、高血压、ALT、胆固醇、HBV DNA、抗病毒治疗及抗血小板治疗。
- 他汀使用28-365、366-730、731-1095及>1095累计defined daily doses的调整后HR(95%CI)分别为0.63(0.31-1.29)、0.51(0.21-1.25)、0.32(0.07-1.36)和0.17(0.06-0.48)。
- 亚组分析显示,他汀使用与HCC风险降低的关联在所有预设亚组中均观察到。
临床怎么用
- 在慢性HBV感染者中,他汀使用与HCC风险降低相关,支持他汀可能的化学预防作用,但需前瞻性研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Statins have pleiotropic effects that may include chemoprevention. Several observational studies have suggested that statins may prevent hepatocellular carcinoma (HCC), but they have not yet been fully studied in patients with chronic hepatitis B virus (HBV) infections. APPROACH AND RESULTS: A hospital-based retrospective cohort of 7,713 chronic HBV-infected individuals between January 2008 and December 2012 were analyzed. The primary outcome was the development of HCC. Patients who used statins for at least 28 cumulative defined daily doses during the follow-up period were defined as statin users (n = 713). The association between the use of statin and the incidence of HCC was analyzed using the multivariable Cox regression model with time-dependent covariates. During a median follow-up of 7.2 years (min-max: 0.5-9.9), HCC newly developed in 702 patients (9.1%). Statin use was associated with a lower risk of HCC (adjusted hazard ratio = 0.36, 95% confidence interval: 0.19-0.68, adjusted for age, sex, cirrhosis, diabetes, hypertension, serum alanine aminotransferase, cholesterol, HBV DNA level, antiviral treatment, and antiplatelet therapy). The observed benefit of the statin use was dose-dependent (adjusted hazard ratio [95% confidence interval], 0.63 [0.31-1.29]; 0.51 [0.21-1.25]; 0.32 [0.07,1.36]; and 0.17 [0.06, 0.48] for patients with statin use of 28-365, 366-730, 731-1095, and more than 1,095 cumulative defined daily doses, respectively). In subgroup analysis, the association between statin use and reduced risk of HCC was observed in all prespecified subgroups analyzed. CONCLUSION: Statin use was associated with a reduced risk of HCC development in chronic HBV-infected patients, suggesting that statins may have a chemopreventive role in this population. These findings warrant a prospective evaluation.
引用
- Goh MJ, Sinn DH, Kim S, et al. Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. Hepatology. 2020. PMID: 31556128. doi:10.1002/hep.30973
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。